Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Australia
Western Pacific
Clear all
Type of publications
NITAG documentation
(89)
Scientific publications
(3)
Systematic reviews (SYSVAC)
(6)
Topics
Regions
Western Pacific
(98)
Eastern Mediterranean
(8)
Countries
Australia
(98)
China
(64)
Japan
(3)
Mongolia
(1)
New Zealand
(10)
South Korea
(8)
Diseases
COVID-19
(29)
Haemophilus influenzae type B
(1)
Hepatitis A
(1)
Hepatitis B
(2)
Herpes zoster
(1)
Human papillomavirus (HPV)
(9)
Influenza
(10)
Japanese encephalitis
(1)
Meningococcal disease
(6)
Mpox // Monkeypox
(1)
Pertussis
(1)
Pneumococcal disease
(2)
Rotavirus
(1)
Tuberculosis
(1)
Publication date
2023
(7)
2022
(13)
2021
(13)
2020
(5)
2019
(7)
2018
(3)
2017
(5)
2016
(6)
2015
(4)
2014
(5)
2013
(6)
2012
(5)
2011
(5)
2010
(6)
2009
(3)
2008
(4)
2007
(1)
Target population
Adults
(2)
All age groups
(2)
Children
(2)
Healthcare workers
(2)
Newborn
(1)
Older adults
(1)
Pregnant women
(1)
Available to download in languages
English (EN)
(78)
98 results found
2023
∙
Middleton, Bianca F. Danchin, Margie Fathima, Parveen Bines, Julie E. Macartney, Kristine Snelling, Thomas L.
Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006 - 2021
2023
∙
ATAGI
ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines
2023
∙
ATAGI
ATAGI Update on the COVID-19 Vaccination Program
2023
∙
ATAGI
ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older
2023
∙
ATAGI
ATAGI advice on seasonal influenza vaccines in 2023
2023
∙
ATAGI
ATAGI 2023 booster advice
2023
∙
ATAGI
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
2022
∙
ATAGI
ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine
2022
∙
ATAGI
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
2022
∙
ATAGI
ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register